Ending diagnostic odysseys and inspiring hope
For patients with rare and complex conditions, physicians and other healthcare professionals need trusted answers. Our tests are developed through leading-edge research and unmatched clinical expertise, creating a diagnostics ecosystem that delivers insights that set a new standard in diagnostic care.
Successful patient outcomes are our priority, and we work with hospitals and physicians around the world to elevate diagnostic excellence everywhere. As part of Mayo Clinic’s healthcare system, we understand the best care is provided locally. We complement local expertise by working with clients and logistics organizations to optimize the specimen journey to our laboratories, enabling physicians to get the results they need and patients to remain at home, focused on healing.
Relentless pursuit of answers
Ongoing research propels test development at Mayo Clinic Laboratories, enabling innovative testing that delivers faster, reliable answers to confidently diagnose patients. Our test results not only equip physicians and patients with meaningful diagnostic, prognostic, and therapeutic insights, they also provide hope for a healthier future.
Experience and expertise you can trust
Mayo Clinic Laboratories’ scientists and physicians are leaders in their fields and able to consult on test selection, utilization, and results interpretation. The exchange of knowledge is a founding principle of Mayo Clinic, and we are committed to sharing lessons we’ve learned with our global collaborators through educational opportunities to help improve care delivery in local practices. This is supported through an expansive library of educational content, podcasts, and stories that showcase breakthroughs in test development and perspectives from Mayo Clinic experts.
Access to groundbreaking diagnostics
Driven by an instinct to innovate, we transform scientific discoveries into meaningful advancements in diagnostic testing. Supported by a robust network of Mayo Clinic physicians and scientists and forward-thinking laboratory partners, we foster access to new and advanced testing, much of which is unavailable elsewhere. This integration connects physicians and hospitals around the world with multiple innovative solutions all in one place to support better patient outcomes.
“We treat all of the specimens we receive with the same high degree of care and quality, regardless of where the sample is coming from. We could be testing a sample from a patient that lives in Rochester, Minnesota, or from someone that lives halfway across the world.”
Bobbi Pritt, M.D., Director of the Clinical Parasitology Laboratory
OUR DIFFERENCE
News and updates
The latest
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.
Since being diagnosed with Graves’ disease, Ryan Black has come to know all too well the pain and discomfort of frequent blood draws. But rather than wallow in self-pity, the teen is spending her time trying to make blood draws easier and less painful for others like her. And she’s doing it with research from Mayo Clinic.
Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for carriers and individuals clinically affected by the most common form of CAH.
Starting mid-November, you will notice enhancements to MayoClinicLabs.com. We are building a better website for you, our clients, to ensure the best experience possible. We’re moving toward a simpler, more intuitive and customized experience, making it easier to do business with us.
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.
The last installment of our 50th Anniversary series explores how Mayo Clinic Laboratories pioneered best practices in the area of specimen accessioning and delivery.
Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' PCR assay that identifies two recently described staphylococcus species. The assay is unique in its ability to distinguish the new organisms from Staphylococcus aureus, providing clearer results that ultimately improve patient care.
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
In this episode of Lab Medicine Rounds, Joseph Yao, M.D., Associate Professor of Laboratory Medicine and Pathology and Medicine, and Assistant Professor of Microbiology at the Mayo Clinic, discusses lessons learned from navigating the current COVID-19 pandemic.
Mayo Clinic Laboratories’ call center has a new outgoing caller ID number for any follow up client communications.
In part three of the 50th Anniversary series, Mayo Clinic Laboratories looks further outside the walls of Mayo Clinic. With the belief that the latest in diagnostic testing should be available to any patient, no matter where they are located, the sales force was born.
It can be hard to know when to use a rapid at-home COVID-19 test and how to interpret the results. Dr. Binnicker reviews the pros and cons of these tests, and explains when you need to get tested by a lab.
In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity and 100% specificity. This is the first assay of its kind that can detect viral antigens “directly from clinical specimens” such as nasopharyngeal swabs. Mass spectrometry is a sensitive technique used to detect, identify, and quantitate molecules present in a sample.